Drug Profile
Buntanetap - Annovis Bio
Alternative Names: (+)-(3aR)-phenserine; (+)-phenserine; ANVS-401; ANVS-405; ANVS402; Buntanetap tartrate; Posiphen; Posiphen TartrateLatest Information Update: 23 Feb 2024
Price :
$50
*
At a glance
- Originator National Institute on Aging; National Institutes of Health (USA); Raptor Pharmaceutical Corp
- Developer Annovis Bio; Cenomed BioSciences; Rockefeller University; University of California at Los Angeles
- Class Antidementias; Antidotes; Antiparkinsonians; Nootropics; Phenylcarbamates; Small molecules; Vascular disorder therapies
- Mechanism of Action Acetylcholinesterase inhibitors; Alpha-synuclein inhibitors; Amyloid beta-protein precursor inhibitors; HD protein inhibitors; Tau protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Parkinson's disease
- Phase II/III Alzheimer's disease
- Phase II Lewy body disease; Mild cognitive impairment
- Phase I Down syndrome; Frontotemporal dementia; Stroke; Traumatic brain injuries
- No development reported Huntington's disease; Poisoning
Most Recent Events
- 13 Feb 2024 Annovis Bio completes a phase II/III trial in Alzheimer's disease (In adults, In the elderly) in USA (PO) (NCT05686044)
- 24 Jan 2024 Annovis Bio files for patent protection with USPTO for buntanetap in USA
- 06 Dec 2023 Annovis Bio completes phase-III trial for Parkinson's disease in USA, Spain, Hungary, Poland, France, Italy and Germany (NCT05357989)